Companion Diagnostics (CDx) Symposium

Scheduled For: Wednesday, November 2nd, 2016 View all Events

Date: November 2, 2016
 
Panel: Pathogenomic Biomarker Integration in the Immunotherapy Era: Lessons from the Clinical Laboratory
   

  • Integration of test findings in the clinical laboratory to assist in patient segmentation
  • Sample utilization for multiple testing modalities
  • Implementation of novel biomarkers
Panelist: Boaz Kurtis, MD
Medical Director
Cancer Genetics, Inc.
 

Website:

 

Companion Diagnostics Symposium

 
Location: Edison, New Jersey

Panel: Building Strategic CRO Partnerships for Biomarker and CDx Centric Clinical Trials
 
Panelists: Kamala Maddali, DVM, PhD
Vice President, Biopharma Collaborations and Companion Diagnostics
Cancer Genetics, Inc.Leslie Abad, MS
Senior Director, Biopharma Market Development and Collaborations
Cancer Genetics, Inc.
 
Website: Companion Diagnostics Symposium
 

Panel: It’s Time for Innovative CDx Planning Strategies in Immuno-Oncology
 
Panelist: Kamala Maddali, DVM, PhD
Vice President, Biopharma Collaborations and Companion Diagnostics
Cancer Genetics, Inc.
 
Website: Companion Diagnostics Symposium
 

Pre-Event Webinar: LDTs in Immuno-Oncology Workshop: Translating Cancer Research into Targeted Therapeutics
  Sub Topics:

  • Cancer and Immune surveillance
  • Mechanisms of immune evasion: focus on IL10
  • Practical aspects of targeting PD1-PD-L1 interaction

Key Takeaways:

  1. Cancer utilizes multiple axis of immune suppression
  2. Cytokines have pleiotropic effect on tumor and its microenvironment
  3. Know your biomarkers: many shades (intensity) of PD-L1 detected by different antibody clones using different IHC platforms.
Speaker: Rita Shaknovich, MD, PhD
Group Medical Director and VP of Hematopathology
Cancer Genetics, Inc.
 
Recorded Webinar: October 13, 2016
link
 
 
Meet With Us

Meet With Us

We would like to hear from you. Please complete the form below to arrange a meeting with one of our leaders during the conference to talk with you and discuss solutions to your central laboratory and biomarker service needs.

First
Last
:
Sending